Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5959 Harry Hines Blvd. Ste. 420, Dallas, TX, 75390-8887, USA.
Division of Pulmonary Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Dig Dis Sci. 2023 Jan;68(1):304-311. doi: 10.1007/s10620-022-07524-6. Epub 2022 May 11.
While hepatitis A and B are well-known causes of acute liver failure (ALF), few well-documented cases of hepatitis C virus (HCV) infection (absent preexisting liver disease or other liver insults) have been described that result in ALF. We reviewed the Acute Liver Failure Study Group registry for evidence of HCV as a primary or contributing cause to ALF.
From January 1998 to January 2017, 2,332 patients with ALF (INR ≥ 1.5, any degree of hepatic encephalopathy) and 667 with acute liver injury (ALI; INR ≥ 2.0, no hepatic encephalopathy) were enrolled. Anti-HCV testing was done routinely, with confirmatory RT-PCR testing for HCV RNA where necessary.
A total of 136 patients were anti-HCV-antibody positive, as follows: 56 HCV RNA negative, 65 HCV RNA positive, and 8 with no result nor sera available for testing. Only three subjects with ALI/ALF were determined to represent acute HCV infection. Case 1: 47-year-old female with morbid obesity (BMI 52.4) developed ALF and recovered, experiencing anti-HCV seroconversion. Case 2: 37-year-old female using cocaine presented with ALI and fully recovered. Case 3: 54-year-old female developed ALF requiring transplantation and was anti-HCV negative but viremic prior to transplant experiencing anti-HCV seroconversion thereafter. Among 1636 APAP overdose patients, the 52 with concomitant chronic HCV had higher 3-week mortality than the 1584 without HCV (31% vs 17%, p = 0.01).
ALI/ALF solely related to acute hepatitis C infection is very rare. Chronic HCV infection, found in at least 65 (2.2%) of ALI/ALF patients studied, contributed to more severe outcomes in APAP ALI/ALF; ClinicalTrials.gov number, NCT000518440. Trial Registration ClinicalTrials.gov number NCT000518440.
虽然甲型肝炎和乙型肝炎是急性肝衰竭(ALF)的已知病因,但很少有丙型肝炎病毒(HCV)感染(无先前存在的肝病或其他肝损伤)引起 ALF 的明确记录病例。我们回顾了急性肝衰竭研究组的登记处,以寻找 HCV 作为 ALF 的主要或促成原因的证据。
从 1998 年 1 月至 2017 年 1 月,共纳入 2332 例 ALF(INR≥1.5,任何程度的肝性脑病)和 667 例急性肝损伤(ALI;INR≥2.0,无肝性脑病)患者。常规进行抗 HCV 检测,必要时进行 HCV RNA 的逆转录聚合酶链反应(RT-PCR)检测以确认。
共有 136 例患者抗 HCV 抗体阳性,具体情况如下:56 例 HCV RNA 阴性,65 例 HCV RNA 阳性,8 例无结果或无血清可供检测。仅有 3 例 ALI/ALF 患者被确定为急性 HCV 感染。病例 1:47 岁女性,病态肥胖(BMI 52.4),发生 ALF 后恢复,出现抗 HCV 血清转换。病例 2:37 岁女性,可卡因使用者,发生 ALI 后完全恢复。病例 3:54 岁女性,发生 ALF 需要移植,抗 HCV 阴性,但移植前病毒血症,此后出现抗 HCV 血清转换。在 1636 例对乙酰氨基酚过量患者中,52 例合并慢性 HCV 的患者的 3 周死亡率高于 1584 例无 HCV 的患者(31% vs 17%,p=0.01)。
仅与急性丙型肝炎感染相关的 ALI/ALF 非常罕见。在研究的至少 65 例(2.2%)ALI/ALF 患者中发现的慢性 HCV 感染导致对乙酰氨基酚引起的 ALI/ALF 患者的结局更严重;临床试验注册号 NCT000518440。